TipRanks
Advertisement
Advertisement

JP:4547 Stock Latest News

Kissei Pharmaceutical Advances Share Buyback Program on Tokyo Stock Exchange
Company AnnouncementsKissei Pharmaceutical Advances Share Buyback Program on Tokyo Stock Exchange
7d ago
Kissei Pharmaceutical Reports Progress on Share Buyback Program
PremiumCompany Announcements
Kissei Pharmaceutical Reports Progress on Share Buyback Program
1M ago
Kissei Pharmaceutical Finalizes Adjusted Treasury Share Disposal for Employee Stock Plan
PremiumCompany Announcements
Kissei Pharmaceutical Finalizes Adjusted Treasury Share Disposal for Employee Stock Plan
2M ago
Kissei Pharmaceutical Reports No Treasury Share Purchases in July Under Ongoing Buyback Plan
PremiumCompany Announcements
Kissei Pharmaceutical Reports No Treasury Share Purchases in July Under Ongoing Buyback Plan
2M ago
Kissei Pharmaceutical Cuts Earnings Forecasts on Weak TAVNEOS Sales
PremiumCompany Announcements
Kissei Pharmaceutical Cuts Earnings Forecasts on Weak TAVNEOS Sales
2M ago
Kissei Pharmaceutical Highlights Q1 FY2026 Results and R&D Pipeline Focus
PremiumCompany AnnouncementsKissei Pharmaceutical Highlights Q1 FY2026 Results and R&D Pipeline Focus
2M ago
Kissei Pharmaceutical Posts Mixed Q1 Results, Lifts Dividends but Cuts FY2027 Outlook
Premium
Company Announcements
Kissei Pharmaceutical Posts Mixed Q1 Results, Lifts Dividends but Cuts FY2027 Outlook
2M ago
Kissei Pharmaceutical Co (KSPHF) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Kissei Pharmaceutical Co (KSPHF) Q1 Earnings Cheat Sheet
3M ago
Kissei Pharmaceutical Completes Treasury Share Disposal for Executive Restricted Stock
PremiumCompany Announcements
Kissei Pharmaceutical Completes Treasury Share Disposal for Executive Restricted Stock
3M ago
Kissei Pharmaceutical Reports No Share Buybacks Yet Under 2026 Repurchase Program
PremiumCompany Announcements
Kissei Pharmaceutical Reports No Share Buybacks Yet Under 2026 Repurchase Program
3M ago
Kissei Faces EU Setback as EMA Backs Revocation of TAVNEOS Authorization
PremiumCompany Announcements
Kissei Faces EU Setback as EMA Backs Revocation of TAVNEOS Authorization
4M ago
Kissei Pharmaceutical Grants Restricted Stock to Board Members and Officers
PremiumCompany Announcements
Kissei Pharmaceutical Grants Restricted Stock to Board Members and Officers
4M ago
Kissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
PremiumCompany AnnouncementsKissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
4M ago
Kissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
Premium
Company Announcements
Kissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
5M ago
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
Premium
Company Announcements
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
5M ago
Kissei Restricts TAVNEOS Use in Japan After Global Safety and Data Concerns
PremiumCompany Announcements
Kissei Restricts TAVNEOS Use in Japan After Global Safety and Data Concerns
5M ago
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
PremiumCompany Announcements
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
5M ago
Kissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
PremiumCompany Announcements
Kissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
5M ago
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
PremiumCompany Announcements
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
5M ago
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
PremiumCompany AnnouncementsKissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
5M ago
KSPHF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
KSPHF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
Premium
Company Announcements
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >